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 Over 10% of hospital inpatients 
receive treatment with 
glucocorticoids 1 and yet the 
incidence of steroid diabetes 
(SD), and therefore monitoring 
requirements, in these patients 
is unknown. Acute illness can 
also induce hyperglycaemia 
through neuroendocrine and 
inflammatory responses, 2 which 
may be exacerbated by use of 
glucocorticoids. 
 We determined the incidence of 
SD in acute medical admissions and 
whether SD corresponds to illness 
severity rather than to the dose of 
glucocorticoid administered. 
 This was a retrospective case-note 
review of inpatients who received 
treatment with glucocorticoids 
(dose ≥10 mg prednisolone once 
daily, or equivalent) 3 for ≥24 hours 
in an acute medical admissions 
unit. We excluded patients using 
glucocorticoid therapy immediately prior to hospitalisation (other 
than inhaler or topical therapy); those with accident & emergency 
(A&E) department triage glucose ≥11.1 mmol/L, length of stay 
<24 hours, and diabetes mellitus (any of medical history, glycated 
haemoglobin ≥6.5% before or up to 3 months after admission, 
any glucose lowering therapy). A consecutive series was sought 
until n=100 in the study cohort. 
 New hyperglycaemia (capillary glucose ≥11 mmol/L after 
initiation of glucocorticoid therapy) was considered SD. 2,4 Glucose 
values were evaluated for up to 7 days after admission. The 
National Early Warning Score (NEWS) was used to determine 
illness severity. Glucocorticoids were converted to equivalent 
potencies to allow dose comparison; 1 steroid unit ≡ 5 mg 
prednisolone. 3 Data are mean (standard deviation) unless 
described. Local Research & Innovation approval was sought and 
we were advised that ethical approval was not required. 
 Between July 2015 and April 2017, 498 patients with an 
acute medical admission received glucocorticoids of ≥10 mg 
prednisolone per day (or equivalent) for at least 24 hours. We 
excluded n=268 without glucose monitoring; a further n=130 with 
pre-existing diabetes were also excluded, leaving 100 patients 
for analysis. Exacerbation of pulmonary disease constituted the 
reason for admission for over half the cohort. The incidence of SD 
was 14%. Median duration of admission before SD was identified 
 Greater illness severity characterises steroid diabetes 
following acute hospitalisation 
was 2.5 days (interquartile range [IQR] 1–4). Patients with SD 
had higher NEWS at admission and higher peak NEWS during 
their hospitalisation (Table  1 ) but no difference in type of steroid, 
nor mean steroid dose. Glucose concentration from the A&E 
department did not predict likelihood of SD (Table  1 ). 
 Patients developing SD following acute hospitalisation had 
greater illness severity than those maintaining normoglycaemia, 
whereas the steroid dose (equivalent to 35 mg prednisolone 
daily) was no different. The incidence of SD that we found (14%) 
is similar to Umpierrez  et al 5 who reported hyperglycaemia in 
12% of a general medical inpatient population (with no history 
of diabetes), although in that series the use of glucocorticoids 
was not reported. We hypothesise that exogenous glucocorticoid 
therapy contributes little to the pathogenesis of hyperglycaemia 
with acute hospitalisation. Use of resource intensive glucose 
monitoring may be better directed to those of greater 
illness severity than to all hospitalised patients treated with 
glucocorticoids. This requires evaluation. ■ 
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 Table 1.  Characteristics of steroid diabetes and normal glucose group 
Parameter Steroid diabetes 
n=14 
Normal glucose 
n=86 
 p value 
Age, years# 64.9 (16.0) 61.3 (18.0) 0.498 
 Gender Male 6 (43%) 40 (47%)
Female 8 (57%) 46 (53%) 0.799
 Type of steroid Prednisolone 11 (79%) 51 (59%)
Hydrocortisone 1 (7%) 26 (30%) 0.257
Dexamethasone 1 (7%) 7 (8%)
Methylprednisolone 1 (7%) 2 (2%)
 Relative daily steroid dose, steroid unit* 6.0 (6.0–10.9) 7.3 (6.0–8.7) 0.303
 Admission NEWS* 6 (3–9) 4 (2–6) 0.041
 Maximum NEWS* 8 (5–9) 6 (3–8) 0.048
 A&E capillary glucose, mmol/L* 6.1 (5.3–10.0) 6.0 (5.3–7.0) 0.195
 Length of stay, days* 7.0 (4.8–16.5) 5.0 (3.0–8.0) 0.113
 Inpatient mortality 2 (14%) 5 (6%) 0.249
 # = mean (standard deviation); * = median (interquartile range); NEWS = National Early Warning Score 
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